Literature DB >> 1761106

Creutzfeldt-Jakob disease among Libyan Jews.

A D Korczyn1.   

Abstract

The focus of CJD among Jews of Libyan origin has been recognized for two decades, but the reasons underlying it were unknown. Prevailing views suggested transmission from sheep infected with scrapie. However, recent data show that in fact CJD in this ethnic group is a genetically determined disease due to a point mutation on the codon 200 of the prion protein gene. The clinical characteristics of CJD in this group, and particularly the less common periodic activity in the EEG, are reviewed. New findings include peripheral neuropathy of the demyelinating type in two cases, presumably due to involvement of Schwann cells. The pathophysiology of the disease includes, presumably, a focal post-translational modification of the prior protein, (predisposed by the mutation). Later, the disease progresses through cell-to-cell transmission.

Entities:  

Mesh:

Year:  1991        PMID: 1761106     DOI: 10.1007/bf00143127

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  17 in total

1.  [Breakthrough in Creutzfeldt-Jakob disease].

Authors:  A D Korczyn
Journal:  Harefuah       Date:  1991-01-01

2.  Mutation in codon 200 of scrapie amyloid protein gene in two clusters of Creutzfeldt-Jakob disease in Slovakia.

Authors:  L G Goldfarb; E Mitrová; P Brown; B K Toh; D C Gajdusek
Journal:  Lancet       Date:  1990-08-25       Impact factor: 79.321

3.  Spongiform encephalopathy in an Israeli born to immigrants from Libya.

Authors:  P Nisipeanu; B el ad; A D Korczyn
Journal:  Lancet       Date:  1990-09-15       Impact factor: 79.321

4.  Identical mutation in unrelated patients with Creutzfeldt-Jakob disease.

Authors:  L G Goldfarb; P Brown; D Goldgaber; R M Garruto; R Yanagihara; D M Asher; D C Gajdusek
Journal:  Lancet       Date:  1990-07-21       Impact factor: 79.321

5.  Creutzfeldt-jakob disease: focus among Libyan Jews in Israel.

Authors:  E Kahana; M Alter; J Braham; D Sofer
Journal:  Science       Date:  1974-01-11       Impact factor: 47.728

6.  [Creutzfeld-Jakob disease and its relation to pre-senile dementia].

Authors:  M Behar; C Sroka; M Elian; E Kott; A Korczyn; B Bornstein; U Sandbank
Journal:  Harefuah       Date:  1969-10-01

7.  Clinical and molecular genetic study of a large German kindred with Gerstmann-Sträussler-Scheinker syndrome.

Authors:  P Brown; L G Goldfarb; W T Brown; D Goldgaber; R Rubenstein; R J Kascsak; D C Guiroy; P Piccardo; J W Boellaard; D C Gajdusek
Journal:  Neurology       Date:  1991-03       Impact factor: 9.910

8.  Letter: Creutzfeldt-Jakob disease: hypothesis for high incidence in Libyan Jews in Israel.

Authors:  L Herzberg; B N Herzberg; C J Gibbs; W Sullivan; H Amyx; D C Gajdusek
Journal:  Science       Date:  1974-11-29       Impact factor: 47.728

9.  Mutation of the prion protein in Libyan Jews with Creutzfeldt-Jakob disease.

Authors:  K Hsiao; Z Meiner; E Kahana; C Cass; I Kahana; D Avrahami; G Scarlato; O Abramsky; S B Prusiner; R Gabizon
Journal:  N Engl J Med       Date:  1991-04-18       Impact factor: 91.245

10.  Familial dementia with PrP-positive amyloid plaques: a variant of Gerstmann-Sträussler syndrome.

Authors:  D Nochlin; S M Sumi; T D Bird; A D Snow; C M Leventhal; K Beyreuther; C L Masters
Journal:  Neurology       Date:  1989-07       Impact factor: 9.910

View more
  9 in total

1.  The EEG in E200K familial CJD: relation to MRI patterns.

Authors:  Shmuel A Appel; Joab Chapman; Isak Prohovnik; Chen Hoffman; Oren S Cohen; Ilan Blatt
Journal:  J Neurol       Date:  2011-08-12       Impact factor: 4.849

2.  Characterization of sleep disorders in patients with E200K familial Creutzfeldt-Jakob disease.

Authors:  Oren S Cohen; Joab Chapman; Amos D Korczyn; Naama Warman-Alaluf; Yael Orlev; Gili Givaty; Zeev Nitsan; Shmuel Appel; Hanna Rosenmann; Esther Kahana; Dalia Shechter-Amir
Journal:  J Neurol       Date:  2014-12-02       Impact factor: 4.849

3.  Familial Creutzfeldt-Jakob disease with the E200K mutation: longitudinal neuroimaging from asymptomatic to symptomatic CJD.

Authors:  Oren S Cohen; Joab Chapman; Amos D Korczyn; Zeev Nitsan; Shmuel Appel; Chen Hoffmann; Hanna Rosenmann; Esther Kahana; Hedok Lee
Journal:  J Neurol       Date:  2014-12-19       Impact factor: 4.849

4.  The Creutzfeldt-Jakob disease (CJD) neurological status scale: a new tool for evaluation of disease severity and progression.

Authors:  O S Cohen; I Prohovnik; A D Korczyn; L Ephraty; Z Nitsan; R Tsabari; S Appel; H Rosenmann; E Kahana; J Chapman
Journal:  Acta Neurol Scand       Date:  2011-02-08       Impact factor: 3.209

5.  Tau and 14-3-3 of genetic and sporadic Creutzfeldt-Jakob disease patients in Israel.

Authors:  Zeev Meiner; Esther Kahana; Fanny Baitcher; Amos D Korczyn; Joab Chapman; Oren S Cohen; Ron Milo; Judith Aharon-Perez; Oded Abramsky; Ruth Gabizon; Hanna Rosenmann
Journal:  J Neurol       Date:  2010-09-09       Impact factor: 4.849

6.  Clinical heterogeneity and unusual presentations of Creutzfeldt-Jakob disease in Jewish patients with the PRNP codon 200 mutation.

Authors:  J Chapman; P Brown; L G Goldfarb; A Arlazoroff; D C Gajdusek; A D Korczyn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-10       Impact factor: 10.154

7.  Unusual presentations in patients with E200K familial Creutzfeldt-Jakob disease.

Authors:  O S Cohen; I Kimiagar; A D Korczyn; Z Nitsan; S Appel; C Hoffmann; H Rosenmann; E Kahana; J Chapman
Journal:  Eur J Neurol       Date:  2016-01-25       Impact factor: 6.089

8.  The insomnia phenotype in genetic Creutzfeldt-Jakob disease based on the E200K mutation.

Authors:  Eva Feketeova; Dominika Jarcuskova; Alzbeta Janakova; Marianna Vitkova; Jozef Dragasek; Zuzana Gdovinova
Journal:  Prion       Date:  2019-01       Impact factor: 3.931

Review 9.  Characterization of mutations in PRNP (prion) gene and their possible roles in neurodegenerative diseases.

Authors:  Eva Bagyinszky; Vo Van Giau; Young Chul Youn; Seong Soo A An; SangYun Kim
Journal:  Neuropsychiatr Dis Treat       Date:  2018-08-14       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.